The Impact of Nutrition on the Onset, Course of Disease and Quality of Life of Patients with Laryngopharyngeal Reflux

Abstract

Research background. The role of dietary habits of patients with laryngopharyngeal reflux (LPR) is comparatively underexplored. The aim of the study is to examine dietary habits, onset and course of the disease as well as the quality of life of patients with LPR. Experimental approach. The results of the modified food frequency questionnaire (FFQ-m) and laryngopharyngeal reflux health-related quality of life (LPR-HRQL) questionnaires were compared between subjects with and without LPR. There were a total of 100 subjects with LPR and 65 subjects in the control group. The group of subjects with LPR was further randomly divided into two subgroups; the first subgroup was treated with esomeprazole at a dose of 20 mg twice daily combined with the instructions for dietary and general lifestyle changes, and the other with pantoprazole at a dose of 20 mg twice daily combined with the instructions for dietary and general lifestyle changes. Participants were instructed to fill out FFQ-m and LPR-HRQL questionnaires immediately after the initial examination and then after control examinations 30 and 60 days after the initial examination. Results and conclusions. Patients with LPR consume more food with high reflux potential, drink more carbonated drinks and juices and have a worse quality of life than the control group (p

Alternate abstract:

Pozadina istraživanja. Uloga prehrambenih navika bolesnika u razvoju laringofaringealnog refluksa (LPR) relativno je nedovoljno istražena. Svrha je rada bila ispitati prehrambene navike, početak i tijek bolesti te kvalitetu života bolesnika s LPR-om. Eksperimentalni pristup. Uspoređeni su rezultati modificiranog upitnika o učestalosti konzumacije hrane i pića (FFQ-m) i upitnika kvalitete života povezane sa LPR-om (LPR-HRQL) ispitanika sa LPR-om i bez njega. Ukupno je bilo 100 ispitanika s LPR-om i 65 ispitanika u kontrolnoj skupini. Skupina ispitanika s LPR-om je zatim nasumično podijeljena u dvije podskupine; prva podskupina liječena je esomeprazolom u dozi od 20 mg dva puta dnevno u kombinaciji s uputama za promjenu prehrane i stila života, a druga pantoprazolom u dozi od 20 mg dva puta na dan uz upute za promjenu prehrane i stila života. Ispitanici su ispunili FFQ-m i LPR-HRQL upitnike odmah nakon inicijalnog pregleda, te nakon kontrolnih pregleda obavljenih 30 i 60 dana nakon inicijalnog. Rezultati i zaključci. Ispitanici s LPR-om konzumiraju više hrane s visokim refluksnim potencijalom, piju više gaziranih pića i sokova te imaju lošiju kvalitetu života od kontrolne skupine (p